Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2019

Mini Oral session - Genitourinary tumours

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Date

22 Nov 2019

Session

Mini Oral session - Genitourinary tumours

Topics

Tumour Site

Prostate Cancer

Presenters

Shahneen Sandhu

Citation

Annals of Oncology (2019) 30 (suppl_9): ix183-ix202. 10.1093/annonc/mdz446

Authors

S.K. Sandhu1, M. Hussain2, J. Mateo3, K. Fizazi4, F. Saad5, N. Shore6, K. Chi7, O. Sartor8, N. Agarwal9, D. Olmos10, A. Thiery-Vuillemin11, P. Twardowski12, N. Mehra13, C. Goessl14, J. Kang14, J. Burgents15, W. Wu14, A. Kohlmann16, C. Adelman16, J. de Bono17

Author affiliations

  • 1 -, Peter MacCallum Cancer Centre, - - Melbourne/AU
  • 2 -, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago/US
  • 3 -, Vall d’Hebron Institute of Oncology, Barcelona/ES
  • 4 -, Institut Gustave Roussy, University of Paris Sud, Villejuif/FR
  • 5 -, Centre Hospitalier de l’Université de Montréal/CRCHUM, Montreal/CA
  • 6 -, Carolina Urologic Research Center, Myrtle Beach/US
  • 7 -, BC Cancer Agency, Vancouver/CA
  • 8 -, Tulane University School of Medicine, New Orleans/US
  • 9 -, Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City/US
  • 10 -, Spanish National Cancer Research Centre (CNIO), & Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Madrid/ES
  • 11 -, CU-PH Medical Oncology Unit, CHU Besançon, Besançon/FR
  • 12 -, City of Hope National Medical Center, Duarte/US
  • 13 -, Radboud University Medical Center, Nijmegen/NL
  • 14 -, AstraZeneca, Gaithersburg/US
  • 15 -, Merck & Co., Inc., Kenilworth/US
  • 16 -, AstraZeneca, Cambridge/GB
  • 17 -, The Institute of Cancer Research and Royal Marsden, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.